Novo Nordisk, FDA and Wegovy and Ozempic

Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.
US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses
US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses: Plainsboro, New Jersey Monday, February 24,
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Novo Nordisk Shares Rise After FDA Clears Shortage of Anti-Obesity Drugs
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Becker's Hospital Review2h
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...
STAT3h
Pharmalittle: We’re reading about rescinded FDA firings, Trump tariff warnings, and more
The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
FDA declares Wegovy® and Ozempic® shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...
FiercePharma3h
Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' fourth quarter
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
Axios Vitals on MSN6h
Copycat Ozempic makers brace for crackdown
Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
devdiscourse1d
Health Sector Shifts: From Drug Approvals to Supply Disruptions
The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...
FiercePharma2h
Lilly banks stockpile of oral GLP-1 drug with potential launch still more than a year away
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...